News Conference News ACC 2025 WARRIOR: No Clear Answers on How to Best Treat INOCA Yael L. Maxwell March 29, 2025
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2024 EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2 Shelley Wood April 07, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup L.A. McKeown March 09, 2023
News Conference News ACC 2023 BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF L.A. McKeown March 06, 2023
News Conference News ACC 2023 Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies Caitlin E. Cox February 23, 2023
News Conference News ACC 2022 POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery Todd Neale April 06, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM Yael L. Maxwell April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Conference News ACC 2018 Perioperative Beta-blockade for Noncardiac Surgery Increases Death, Stroke at 1 Year Yael L. Maxwell March 15, 2018
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2016 EARLY-BAMI: No Reduction in Infarct Size With IV Metoprolol Before Primary PCI Caitlin E. Cox April 03, 2016
News Conference News ACC 2015 BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease L.A. McKeown March 16, 2015